Gene Therapy Market To Surge $4.6B By 2027: Focus On CVDs And Orphan Diseases – Technavio
Technavio forecasts significant growth in the global gene
therapy market, expecting an increase of USD 4,613.9 million between 2022 and
2027, with a compound annual growth rate (CAGR) of 19.91%. This surge is
attributed to heightened research in gene therapy for cardiovascular diseases
(CVDs) and orphan diseases. Companies are redirecting their research and
development efforts toward gene therapies for CVDs due to their high prevalence
in the adult population, especially those over 65. The focus is on developing
therapies for immediate treatments, such as MYDICAR, a gene transfer therapy in
Phase II development for heart failure.
The market segmentation by therapy areas includes oncology,
CNS, ophthalmology, rare diseases, and others, with oncology projected to
experience significant growth. The global gene therapy market is geographically
divided into North America, Europe, Asia, and the Rest of the World, with North
America expected to contribute 39% to the market's growth. The U.S. has become
a lucrative market, with increased investments and funding from government
agencies driving gene therapy development.
The vendor landscape is characterized by fragmentation, with
several global and regional vendors. Key vendors include Abeona Therapeutics
Inc., Amgen Inc., Biogen Inc., Gilead Sciences Inc., and Novartis AG. These
companies offer a range of gene therapy solutions, reflecting the industry's
diversity.
Comments
Post a Comment